Knockdown of Glycolysis-Related LINC01070 Inhibits the Progression of Breast Cancer
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study developed a prognostic model using glycolysis-related long non-coding RNAs (lncRNAs) to predict breast cancer outcomes. The model accurately identifies patients with better prognoses, highlighting LINC01070 as a potential biomarker.
Area Of Science
- Oncology
- Molecular Biology
- Genomics
Background
- Glycolysis and long non-coding RNAs (lncRNAs) are implicated in tumor development.
- Identifying reliable biomarkers for breast cancer prognosis is crucial for patient management.
Purpose Of The Study
- To construct a novel prognostic model for breast cancer based on glycolysis-related lncRNAs (GRLs).
- To evaluate the predictive and diagnostic efficacy of the developed prognostic signature.
- To investigate the functional role of a specific GRL, LINC01070, in breast cancer progression.
Main Methods
- Utilized Pearson correlation and Lasso regression analysis on TCGA and GSEA datasets to identify GRLs.
- Constructed a prognostic risk signature based on nine identified GRLs.
- Performed Kaplan-Meier survival, Cox regression, and ROC curve analyses for validation.
- Conducted in vitro assays (clone formation, EdU, Transwell) to assess LINC01070 function.
Main Results
- Identified a nine-GRL prognostic signature with significant predictive value for breast cancer patient survival (AUCs of 0.78, 0.71, 0.71 at 1, 3, 5 years).
- The low-risk group demonstrated a significantly better prognosis.
- Knockdown of LINC01070 inhibited breast cancer cell proliferation and migration.
- The signature exhibited strong diagnostic efficacy and clinical predictive power.
Conclusions
- A novel prognostic risk signature based on GRLs accurately predicts breast cancer patient outcomes.
- LINC01070 serves as a potential biomarker for predicting breast cancer prognosis and warrants further investigation.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...